Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“On July 16, 2014, we entered into a License Agreement (as amended, "Intellia Agreement") with Intellia, LLC (now Intellia Therapeutics, Inc.), under which we granted Intellia an exclusive worldwide license, with the right to sublicense, to certain CRISPR-Cas9 technology for a defined field of human therapeutics in exchange for Intellia stock.”
FILING10-K0001619856-26-000008cik 0001619856disclosed by CRBU
“The increase in collaboration revenue during the year ended December 31, 2025 is due to a $23.7 million increase, primarily in cost reimbursements related to our collaboration with Regeneron Pharmaceuticals, Inc. ("Regeneron")”
FILING10-K0001193125-26-076550cik 0001652130
“Pursuant to the Leaseback Agreement, in exchange for Intellia's grant to us of an exclusive license to certain intellectual property relating to CRISPR-Cas9, including Cas9 chRDNAs, for use solely in the manufacture of our vispa-cel product candidate, we paid Intellia an upfront cash payment of $1.0 million and we will owe up to $23.0 million in potential future regulatory and sales milestones.”
FILING10-K0001619856-26-000008cik 0001619856disclosed by CRBU
“the recognition of $21.0 million of previously eliminated intra-entity profit under our License and Collaboration Agreement with AvenCell Therapeutics, Inc. (the "AvenCell LCA") in the year ended December 31, 2024.”
FILING10-K0001193125-26-076550cik 0001652130
“$9.0 million in revenue that was recognized as a result of the termination of our License, Collaboration and Option Agreement with SparingVision SAS (the "SparingVision LCA")”
FILING10-K0001193125-26-076550cik 0001652130
Watchlist prices, news filtered to it, and its next report on your desk.
Intellia Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · In Vitro & In Vivo Diagnostic Substances
Prev close 11.37 · gapped above the open, then crossed back over prior close. High/low 11.91 at 5:30 am ET, 11.26 at 3:00 pm ET.
Intellia Therapeutics, Inc. has 1 disclosed supplier and 4 disclosed customers. Each one is named in an SEC filing, either Intellia Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
NTLA (Intellia Therapeutics, Inc.) has 1 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: REGN −2.23%, in healthcare.